AFT Pharmaceuticals is a unique pharmaceutical company dedicated to delivering innovative health solutions that make a real difference in people’s lives. With a guiding mission to improve health outcomes, AFT develops, licenses, and distributes a diverse portfolio of pharmaceutical products that includes patented, branded, and generic drugs. Their focus spans both prescription and non-prescription medicines, ensuring a wide range of effective options for healthcare professionals and consumers alike.
Over the past two decades, AFT has rapidly expanded from local beginnings in Australasia to become a global player in the pharmaceutical industry. Their product portfolio is powered by both proprietary research and strategic in-licensing, allowing AFT to bring novel therapies—such as the internationally recognized Maxigesic® pain relief range—to markets across New Zealand, Australia, Asia, and beyond. The company continues to build strong international partnerships and licensing agreements, as recently demonstrated by their collaborations to extend Maxigesic’s reach in the US and Brazil.
AFT’s commitment goes beyond medicines alone—they are actively involved in research and development for new treatments, such as topical therapies for scars, in partnership with leading research organizations. Their ongoing investment in product innovation and customer service sets AFT Pharmaceuticals apart, creating value for patients, investors, and stakeholders while contributing to global healthcare advancement. Whether you’re looking to invest, collaborate, or access their products, AFT is dedicated to making pharmaceuticals that truly make a difference.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
